Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy.

ABSTRACT:

Objective

The Charlson Comorbidity Index (CCI) is a widely utilized assessment tool for evaluating the mortality rate among patients with chronic diseases and tumors. Currently, there is a dearth of research investigating the correlation between CCI and survival rates in advanced pancreatic cancer patients received immunotherapy. Therefore, this study aims to elucidate the association between CCI and survival rates in real-world settings for pancreatic cancer patients received immunotherapy.

Methods

A total of 104 patients with advanced pancreatic cancer who received immunotherapy at the General Hospital of the People's Liberation Army between September 2015 and September 2020 were included in this study. The patients were categorized into two groups based on their Charlson

SUBMITTER: Zhang N 

PROVIDER: S-EPMC11831428 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature